These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 27064194)

  • 21. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.
    Grabowski H; Vernon J
    Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 24. Generic script share and the price of brand-name drugs: the role of consumer choice.
    Rizzo JA; Zeckhauser R
    Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM
    Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract]   [Full Text] [Related]  

  • 28. Generic entry, reformulations and promotion of SSRIs in the US.
    Huskamp HA; Donohue JM; Koss C; Berndt ER; Frank RG
    Pharmacoeconomics; 2008; 26(7):603-16. PubMed ID: 18563951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
    Beall RF; Hardcastle L; Clement F; Hollis A
    Health Policy; 2019 Dec; 123(12):1251-1258. PubMed ID: 31601457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The unexpected consequences of generic entry.
    Castanheira M; Ornaghi C; Siotis G
    J Health Econ; 2019 Dec; 68():102243. PubMed ID: 31734583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sharing, samples, and generics: an antitrust framework.
    Carrier MA
    Cornell Law Rev; 2017; 103(1):1-64. PubMed ID: 29236427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
    Rodriguez-Monguio R; Seoane-Vazquez E
    AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.